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Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease, which gradually damages motor 
neurons in the cortex, brainstem, and spinal cord, leading to a progressive deterioration in patients’ fitness and their depen-
dence on others.
Aim of the research: To assess electromyographic parameters and abnormal gait in the course of ALS.
Material and methods: The study covered 20 people with clinically proven or probable ALS diagnosed, determined accord-
ing to the El Escorial criteria. In the study group, 10 patients were affected by the limb onset of the disorder, and the remain-
ing 10 people by the bulbar onset. The analysis covered electromyography and test results: 6-minute walk test and 10-metre 
walk test performed three times within 6 months.
Results: The results of electromyographic parameters and tests were analysed for the whole group and separately for the 
group with bulbar-onset and limb-onset ALS. The statistical analysis of the results has shown that the duration of motor 
unit potential (MUP) is the most useful electromyographic parameter in early diagnosis and monitoring of the course of the 
disease. The increasing abnormal gait in the course of ALS was a clinical reflection of gradually prolonging MUP.
Conclusions: The progressing loss of nerve and muscle function as a result of motor neuron loss is reflected in walking de-
terioration in ALS patients. 2. The gradually increasing MUP duration of particular muscles is concomitant to the increasing 
abnormal gait. The assessment of the MUP duration of particular muscles may serve to monitor the ALS progression.
Streszczenie
Wprowadzenie: Stwardnienie zanikowe boczne (SLA) to nieuleczalna choroba neurodegeneracyjna, która uszkadza w sposób 
postępujący komórki ruchowe kory mózgu, pnia mózgu i  rdzenia kręgowego, a  także prowadzi do stopniowego pogorszenia 
sprawności pacjentów i ich uzależnienia od otoczenia.
Cel pracy: Ocena parametrów elektromiograficznych oraz zaburzeń chodu w przebiegu SLA.
Materiał i metody: W badaniu wzięło udział 20 osób z klinicznie pewnym lub prawdopodobnym rozpoznaniem SLA ustalonym 
na podstawie kryteriów El Escorial. W grupie 10 badanych osób choroba miała postać kończynową, a u pozostałych 10 – postać 
opuszkową. Analizie poddano wyniki badań elektromiograficznych i wyniki testów: 6-minutowego testu marszowego i 10-me-
trowego testu marszowego, które wykonano trzykrotnie w ciągu 6 miesięcy. Wyniki parametrów elektromiograficznych oraz te-
stów marszowych oceniających sprawność chodu przeanalizowano dla całej badanej grupy oraz odrębnie dla chorych z postacią 
opuszkową i kończynową SLA.
Wyniki: Analiza statystyczna wykazała, że najbardziej przydatnym parametrem elektromiograficznym, który służy do wczesnej 
diagnozy oraz monitorowania przebiegu choroby, jest czas trwania pojedynczych jednostek ruchowych (MUP). Klinicznym od-
zwierciedleniem stopniowego wydłużania się czasu trwania MUP były narastające zaburzenia chodu w przebiegu SLA.
Wnioski: Postępujące ograniczenie funkcji nerwowo-mięśniowych wskutek utraty motoneuronów znajduje odzwierciedlenie 
w upośledzeniu sprawności chodu u pacjentów z SLA. Stopniowo zwiększające się wydłużenie czasu trwania MUP poszczegól-
nych mięśni towarzyszy narastaniu zaburzeń chodu. Ocena czasu trwania MUP poszczególnych mięśni może służyć monitoro-
waniu postępu SLA.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a  progres-
sive, terminal neurodegenerative disease leading to 
upper and lower motor neuron damage, namely dam-
age of the cells located in the cerebral cortex, brain 
stem, and spinal cord [1–3]. The incidence rate of the 
sporadic form amounts on average to 1.9 per 100,000/
year, the frequency of approx. 7 per 100,000 in the 
general population. Recent years have shown an in-
crease in the incidence rate and increased incidence 
rate at a  younger age. The incidence rate in men is 
slightly higher than in women (1.5 : 1), but over the 
age of 70 years the number of men and women lev-
els. Peak ALS incidence rate is observed at the age 
of 65 years; only 10% are diagnosed below the age 
of 45 years and 20% over 70 years [4]. The majority 
of ALS cases are sporadic (SALS), only 5–10% of the 
cases are familial (FALS), mainly inherited in an auto-
somal dominant manner, and with high penetration 
of mutation. The clinical image shows two forms: two 
thirds of the patients suffer from the classical form 
(Charcot disease) simultaneously affecting the upper 
and lower motor neuron; bulbar onset form; progres-
sive muscular atrophy (PMA), which has two variants, 
i.e. flail arm (FA) and pseudopolyneuritic – flail leg 
(FL) – mainly affecting the lower motor neuron; and 
primary lateral sclerosis (PLS). Clinical practice uses 
the distinction of spinal-onset ALS, bulbar-onset ALS, 
and the previously mentioned flail arm and flail leg 
[5–7]. The diagnosis of amyotrophic lateral sclerosis 
is almost solely based on the clinical image supported 
by an electrophysiology study. Five–ten percent of 
the cases constitute incorrect diagnoses. Magnetic 
resonance imaging (MRI), cerebrospinal fluid testing 
(CSF) and some serological tests are performed in or-
der to rule out other ailments that may be the reason 
for the upper and lower motor neuron damage [8–13]. 
Nowadays, the modified El Escorial criteria dating 
back to 1998 are used for the clinical classification of 
ALS [14–17]. Despite many clinical trials and progress 
in the understanding of ALS pathology, there are no 
medications effectively suppressing the development 
of the disease. The only medication with proven ef-
fectiveness in prolonging the ALS patients’ lives is 
riluzole. The Food and Drug Administration (FDA) 
has recently approved a  new drug in the treatment 
of ALS – edaravone – in Japan and the United States. 
It is an intravenous drug, whose precise mechanism 
of treatment of amyotrophic lateral sclerosis is not 
known. Edaravone may be a  viable alternative after 
failed riluzole treatment. Regardless of the form or na-
ture of the onset, amyotrophic lateral sclerosis always 
leads to gradual deterioration in physical fitness of the 
sufferers. The basic functions of movement, which 
make normal existence possible, are gradually lost. 
The comfort of life of ALS patients significantly wors-
ens, they become dependent on their environment 
as regards activities of daily living, and finally they 
require specialist nutrition (percutaneous endoscopic 
gastrostomy – PEG, percutaneous radiologic gastros-
tomy – PRG, or nasogastric tube – NGT) and protec-
tive ventilation [7, 17, 18]. The average survival from 
the first symptoms is approx. 2–3 years for the bulbar 
onset and 3–5 years for the limb onset. Only approx. 
5% of the patients survive more than 10 years [4].
Aim of the research
The aim of the paper was to analyse the electro-
myographic parameters and abnormal gait in the 
course of a half-year observation of ALS patients.
Material and methods
The study covered 20 patients, 5 women and 15 men, 
aged 43 to 85 years (on average 65.5 ±13 years) with 
a clinically certain or possible amyotrophic lateral scle-
rosis diagnosis, determined on the basis of the modi-
fied El Escorial criteria [19]. The group was composed of 
people incidentally reporting for diagnostics, with no 
visible paresis, making it impossible to perform walk 
tests. Moreover, no patient suffered from concomitant 
diseases that could affect their physical fitness. 
The patients were informed about the scope of 
the clinical trial and the electrophysiology study, to 
which they consented verbally. All the patients had 
full neurological examination panel performed along 
with the assessment of the upper and lower motor 
neuron, walk test, and electromyography.
The patients were divided into two groups, based 
on the clinical image: a) bulbar-onset ALS patients; 
b) limb-onset ALS patients.
The patients were examined three times within 
6 months. The preliminary measurement was desig-
nated with the letter A, the next one after 3 months 
with the letter B, and the last one after 6 months with 
the letter C. 
The problem was discussed with the Bioethics 
Committee. In line with the arrangements, the Com-
mittee’s approval to conduct the study was not re-
quired because it was of a  diagnostic character and 
served the purpose of monitoring the course of the 
illness; it was not an experimental study.
The electromyographic study was carried out by 
the authors. In accordance with the recommenda-
tion of the Bioethical Commission, oral consent was 
acquired from the respondents to conduct the study 
and from the persons included in the control group. 
Electromyography was performed with a standard 
method three times. The EMG test was performed us-
ing the needle method with Dantec DCN disposable 
concentric needle electrodes, using the Dantec Key-
point Focus equipment. Muscles from three layers of 
the central nervous system were subject to the proce-
dure: the bulbus, cervical section, and the lumbosa-
cral section of the spinal cord. The following muscles 
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were subject to the procedure: muscle of the tongue 
(12th nerve nucleus), left biceps brachii (C5-C6) (left 
BB), left first dorsal interosseous muscle (C7-Th1) (left 
FDI), right vastus lateralis (L4-L5) (right VL), and right 
tibialis anterior (L5-S1) (right TA). Resting activity and 
the parameters of motor unit potential (MUP) were 
assessed in particular muscles, i.e. duration, ampli-
tude, area, size index (SI), and polyphase potential ra-
tio. The results of electromyographic parameters were 
referred to the standards of the laboratory, created on 
a group of 25 healthy people aged 20–80 years (aver-
age: 51.5 ±32 years). The control group were patients 
reporting no ailments that could affect the electro-
physiological parameters.
The walk test was based on two tests: a 6-minute 
walk test and a 10-metre walk test [20]. The results of 
the tests were referred to the control group. In this 
case, it was a group of 20 healthy people aged 20–80 
years (average: 55 ±28 years), fit as regards walking. In 
the case of the 6-minute walk test, the higher the re-
sult, the better the movement, in the case of the 10-me-
tre walk test, the lower the result, the better the fitness.
The results of walk tests and electromyographic 
parameters were analysed for the whole group and 
separately for the group with bulbar-onset and limb-
onset ALS.
Statistical analysis
The results were subject to statistical analysis with 
the use of descriptive methods and statistical conclu-
sions. Arithmetic mean (x) was calculated for quan-
tity, while standard deviation was adopted as statisti-
cal dispersion. Quality features corresponding to the 
normal distribution were assessed with the use of the 
Shapiro-Wilk test and on the basis of the analysis of 
skewness and kurtosis and standard errors, as well as 
the visual assessment of histograms and Q-Q plots. 
Friedman two-way analysis of variance by ranks 
(Friedman ANOVA) was used for comparison of quan-
titative variables with no distribution similar to the 
standard one. Post hoc analyses were performed with 
the use of the Wilcoxon signed-rank test for dependent 
groups with the Bonferroni correction. The paramet-
ric analysis of variance in an intra-group scheme was 
applied to compare variables with distribution similar 
to normal. Mauchly’s test was used to verify spheric-
ity, and in the case of its lack, the Greenhouse-Geisser 
or Huynh-Feldt corrections were used. In this case, 
the Bonferroni correction was also used. Cochran’s Q 
test was used to compare the quality variable distribu-
tions in dependent groups, while post hoc analyses 
were performed with the use of the McNemar’s test 
with the Bonferroni correction. The maximum per-
missible type I error of α = 0.05 was adopted for all the 
analyses; p ≤ 0.05 was statistically significant. 
All the patients consented verbally to electromyog-
raphy and walk tests for movement fitness assessment. 
Results
In the course of preliminary measurement (A), as 
regards the standard of the laboratory, the majority of 
the patients had correct results as regards the dura-
tion of MUP of the right vastus lateralis (VL) (95%) 
and the right tibialis anterior (TA) (85%) as well as the 
right vastus lateralis polyphase potentials ratio (VL) 
(90%) and the left biceps brachii (BB) (65%). All the 
patients subject to analysis obtained an incorrect re-
sult as regards the amplitude, area, and size index of 
MUP of the left biceps brachii (BB) and the size in-
dex of MUP of the left first dorsal interosseous muscle 
(FDI). The majority presented incorrect results of the 
MUP amplitude of the left FDI muscle and the size 
index of MUP of the right TA muscle (95% each) as 
regards the area and the duration of MUP of the left 
FDI muscle, the MUP amplitude, and area of the right 
VL muscle (90% each) as well as concerning the dura-
tion of the left BB, the MUP amplitude, and area of the 
right TA muscle (85% each). In 80% of the cases there 
were incorrect values of MUP size index of the right 
VL muscle, while in 60% of the cases incorrect values 
of the polyphase potential ratio of the left FDI were 
obtained (Table 1). In the course of the measurement, 
no fasciculation was observed in the majority of sub-
jects, i.e. in 75% in muscles of the tongue, in 65% in 
the left BB, and in 60% in the right VL. In turn, active 
denervation potentials were recorded in all the pa-
tients (these were fibrillation or positive sharp waves) 
in the muscles of the tongue and in the majority in the 
left FDI muscle (95%), the right TA (85%), and the left 
BB and right VL (65% each).
The analysis of walk tests results revealed abnor-
malities in 85% of the patients in the case of the 6-min-
ute walk test and in 80% in the 10-metre walk test.
The analysis of electromyographic parameters 
within half a year in the studied group has shown sta-
tistically significant differences between particular mea-
surements as regards the duration of the motor unit po-
tential (MUP) of the left BB, left FDI, right TA, and right 
VL as regards the MUP amplitude of the right TA, right 
VL, and polyphase potential ratio of the left FDI.
Two-way analyses have shown that the duration 
of MUP of the left BB in patients in the course of the 
A measurement was lower than in the B measurement 
(p = 0.001) and the C measurement (p < 0.001), the 
duration of MUP of the left FDI in the course of the 
A measurement was lower than in the course of the 
B measurement (p < 0.001) and the C measurement 
(p = 0.004), the duration of MUP of the right TA in 
the course of the A measurement was lower than in 
the course of the B measurement (p = 0.001) and the 
C measurement (p = 0.031), and the duration of MUP 
of the right VL in the course of the A measurement 
was lower than in the case of the B measurement 
(p = 0.001) and C measurement (p = 0.011) (Figure 1). 
Moreover, the analyses showed that the multiphase 
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Table 1. Structure of motor unit potential parameters in the course of preliminary measurement and within 6 months in 
the studied group (N = 20)
Muscle Parameter
MUP
Measurement 
moment
Abnormal value N Mean SD
N % of total
Left biceps 
brachii (BB)
Amplitude [µV] A 20 100.00 20 1011.05 279.60
B 20 100.00 20 997.55 312.29
C 20 100.00 20 1017.10 304.27
Area [ms/µV] A 20 100.00 20 1124.71 1124.71
B 19 95.00 20 1831.90 1136.86
C 20 100.00 20 2038.40 1243.73
Duration [ms] A 17 85.00 20 13.17 1.30
B 20 100.00 20 14.25 0.96
C 19 95.00 20 14.24 1.29
Size Index (SI) A 20 100.00 20 1.61 0.33
B 19 95.00 20 1.57 0.40
C 20 100.00 20 1.65 0.47
Polyphase 
potentials (%)
A 7 35.00 20 14.71 8.31
B 11 55.00 20 18.37 10.58
C 9 45.00 20 17.63 10.98
Left first 
dorsal 
interosseous 
(FDI)
Amplitude [µV] A 19 95.00 20 1686.10 1200.56
B 17 85.00 20 2179.30 2540.93
C 18 90.00 20 1658.85 1210.53
Area [ms/µV] A 18 90.00 20 2791.25 2260.86
B 16 80.00 20 2955.40 2320.96
C 19 95.00 20 2999.10 2373.55
Duration [ms] A 18 90.00 20 13.13 1.13
B 19 95.00 20 13.91 0.98
C 19 95.00 20 13.81 1.12
Size Index (SI) A 20 100.00 20 1.85 0.25
B 18 90.00 20 1.89 0.39
C 20 100.00 20 1.86 0.24
Polyphase 
potentials (%)
A 12 60.00 20 21.25 9.62
B 16 80.00 20 23.14 10.42
C 18 90.00 20 30.50 13.39
Right tibialis 
anterior (TA)
Amplitude [µV] A 17 85.00 20 1213.15 279.81
B 13 65.00 20 1263.75 354.65
C 17 85.00 20 1338.20 279.64
Area [ms/µV] A 17 85.00 20 2341.20 684.50
B 14 70.00 20 2359.90 913.44
C 19 95.00 20 2565.25 1072.60
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potentials ratio of the left FDI muscle in the course 
of the A measurement was lower than in the B and C 
measurement (p = 0.032), and the MUP amplitude of 
the right TA in the course of the A measurement was 
lower than in the case of the B and C measurement 
(p = 0.032), and the MUP amplitude of the right VL 
was lower in the A measurement than in the B and C 
measurement (p = 0.032).
As regards the remaining MUP parameters of the 
muscles subjected to testing, analyses showed no sta-
tistically significant differences between particular 
measurement (p > 0.05).
Analysis as regards the potentials of active and 
chronic denervation in all the muscles subjected to 
examination presented no statistically significant dif-
ferences in the course of the 6-month observation of 
patients (p > 0.05). 
The analysis of walk tests within half a  year 
showed that the result of the 10-metre walk test in the 
course of the A measurement was lower than in the 
case of the B measurement (p < 0.001) and C measure-
ment (p = 0.001). In turn, the result of the 6-minute 
walk test during the A measurement was higher than 
in the case of the B measurement (p < 0.001) and the C 
measurement (p < 0.001) (Figures 2 and 3).
The assessment of electromyographic parameters 
in case of the ALS limb onset presented statistically 
significant differences between particular measure-
ments as regards the duration of MUP of the left BB, 
left FDI, right VL, and MUP area of the right VL. Com-
parisons performed multiple times have shown that 
the duration of MUP of the left BB in the course of the 
preliminary A  measurement was lower than in the 
course of the B and C measurement (p = 0.021); of the 
Muscle Parameter
MUP
Measurement 
moment
Abnormal value N Mean SD
N % of total
Duration [ms] A 3 15.00 20 13.46 1.20
B 5 25.00 20 14.60 1.55
C 5 25.00 20 14.10 1.25
Size Index (SI) A 19 95.00 20 1.99 0.37
B 18 90.00 20 2.01 0.41
C 18 90.00 20 2.02 0.48
Polyphase 
potentials (%)
A 8 40.00 20 16.35 13.23
B 11 55.00 20 18.82 10.64
C 12 60.00 20 19.92 11.91
Right vastus 
lateralis (VL)
Amplitude [µV] A 18 90.00 20 1219.35 241.28
B 17 85.00 20 1226.20 261.25
C 19 95.00 20 1323.95 256.20
Area [ms/µV] A 18 90.00 20 2282.90 507.21
B 17 85.00 20 2418.50 758.86
C 17 85.00 20 2611.50 726.37
Duration [ms] A 1 5.00 20 13.82 0.84
B 7 35.00 20 14.71 1.09
C 7 35.00 20 14.37 1.20
Size Index (SI) A 16 80.00 20 1.90 0.29
B 18 90.00 20 1.99 0.36
C 19 95.00 20 2.00 0.32
Polyphase 
potentials (%)
A 2 10.00 20 10.45 4.97
B 6 30.00 20 13.36 9.44
C 4 20.00 20 12.23 4.71
MUP – motor unit potential, N – number, SD – standard deviation. Measurement moment: A – initial measurement, B – measurement after 
3 months, C – measurement after 6 months.
Table 1. Cont.
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left FDI in the course of the A measurement was lower 
than in the case of the B measurement (p = 0.015) and 
during the C measurement (p = 0.043); of the right VL 
in the course of the A measurement was lower than in 
the case of the B measurement (p = 0.028) and in the 
course of the C measurement (p = 0.015), and the area 
of MUP of the right VL in the course of the A mea-
surement was lower than in the case of the B and C 
measurements (p = 0.038) (Figure 4). The remaining 
electromyographic parameters showed no statistically 
significant differences in the course of the half-year 
observation of limb-onset ALS patients. The analysis 
of walk tests results in the patients presented – as in 
the assessment of all the patients subject to testing – 
statistically significant differences, i.e. as regards the 
10-metre walk test the result in the A  measurement 
was lower than in the B measurement (p < 0.001), and 
during the B measurement it was lower than in the 
C measurement (p < 0.001); as regards the 6-minute 
walk test the result was higher in the A measurement 
than in the B measurement (p = 0.001) and in the B 
measurement it was higher than in the C measure-
ment (p < 0.001) (Figures 2 and 3). There were no 
significant differences between the measurements as 
Left biceps brachii                Left first dorsal interosseous
Right tibialis anterior           Right vastus lateralis
10-meter walk; test in the studied group
10-meter walk; test in the group of limb onset ALS patients
10-meter walk; test in the group of bulbar onset ALS patients
Figure 1. Mean duration of MUP, left BB, left FDI, right TA, 
and right VL in the studied group within 6 months
Measurements: A – initial, B – after 3 months, C – after 6 months.
Figure 2. Mean result of the 10-metre walk test within 
6 months in the studied group, in patients with limb-onset 
ALS and bulbar-onset ALS
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Figure 3. Mean results of the 6-minute walk test within 
6 months in the studied group, in the case of limb-onset 
ALS patients and bulbar-onset ALS patients
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Figure 4. Mean MUP duration of the studied muscles with-
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regards the presence of denervation potentials in all 
the muscles subject to testing (p > 0.05). 
The same analysis in the bulbar-onset ALS patient 
group showed statistically significant differences as 
regards the duration of MUP of the left BB, left FDI, 
right TA, right VL, as well as the MUP area of the left 
BB and MUP amplitude of the right TA. Multiple com-
parisons have shown that the duration of MUP of the 
left BB in the course of the A measurement was lower 
than in the case of the B measurement (p = 0.021) and 
in the course of the C measurement (p = 0.021); of the 
left FDI was lower in the case of the A measurement 
than in the course of the B measurement (p = 0.024); 
of the right TA in the course of the B measurement 
was higher than in the course of the A measurement 
(p = 0.027) and the course of the C measurement 
(p = 0.035); of the right VL in the course of the A mea-
surement was lower than in the course of the B mea-
surement (p = 0.021) (Figure 4). Moreover, the MUP 
area of the left BB in the course of the A measurement 
was higher than in the course of the B measurement 
(p = 0.021) and the MUP amplitude of the right TA in 
the course of the A measurement was lower than in 
the course of the B and C measurement (p = 0.005). 
The remaining parameters indicated no statistically 
significant differences in the course of the subsequent 
measurements. Also in this case, the analysis of walk 
tests results within half a year showed significant dif-
ferences, i.e. as regards the 10-metre walk test the re-
sults in the A measurement were lower than in the B 
measurement (p = 0.012) and in the B measurement 
it was lower than in the C measurement (p = 0.003), 
and as regards the 6-minute walk test the result of 
the A  measurement was higher than in the B mea-
surement (p = 0.023) and in the course of the B mea-
surement it was higher than in the C measurement 
(p = 0.001) (Figurs 2 and 3). Moreover, in the case of 
bulbar-onset ALS patients there were no statistically 
significant differences observed as regards the dener-
vation potentials between the measurements.
Discussion
In the case of ALS patients, the most common 
abnormalities observed upon electromyography are 
a record of neurogenic damage nature. The record has 
the features of active denervation and reinnervation. 
The features of acute denervation include fibrillation 
at rest and positive free waves, while the features of 
reinnervation include an increase in the motor unit 
potential parameters (MUP). The ALS-specific fascic-
ulations at rest are also present. 
While analysing their own study, the authors dem-
onstrated fibrillation at rest and positive free waves in 
the course of preliminary assessment in the majority 
of patients, while fasciculation was observed far less 
frequently. The motor unit potential of the examined 
muscles presented increased amplitude, area, size in-
dex, and duration. The results are similar to the find-
ings of Ren et al. [21] and Xu et al. [22]. 
Benaim et al. used multiple function scales to clini-
cally assess the fitness of ALS patients; most often they 
applied the ALS functional rating scale (ALSFRS) [23]. 
Our studies utilised completely different tests to per-
form the walk test, namely a 6-minute walk test and 
a 10-metre walk test. Lorenz et al. monitored the prog-
ress of rehabilitation of patients with incomplete spinal 
cord injury with the use of the tests we applied [20].
Amyotrophic lateral sclerosis naturally leads to the 
imminent loss of nerve and muscle function, which 
clinically leads to amyotrophy or paresis, which de-
teriorate the physical fitness of the patients [24]. As 
the disease progresses, the patients become less and 
less fit, they rely on the help of the family, and finally 
they die shortly afterwards [1]. The results we have 
obtained show that in the case of the majority of pa-
tients, abnormalities as regards the clinical tests cor-
respond to the results of neurophysiological testing, 
which proves earlier findings.
Wijesekera et al. wrote that amyotrophy and mus-
cle paresis are of progressive nature within the course 
of the disease, and as a result they lead to a gradual in-
crease in abnormal gait [4]. These findings correspond 
to ours.
Couratier et al. found that the loss of motor func-
tions is inevitable in the case of ALS patients, it leads 
to deterioration in their fitness, and as the disease pro-
gresses – to severe disability and the patient becoming 
dependent on the environment even in simple activi-
ties of daily living. They used multiple scales to monitor 
the progress of the dysfunction, i.e. the ALS functional 
rating scale, ALS severity scale, Appel scale, Norris 
scale, and Honda scale [18]. The authors obtained simi-
lar results as those mentioned above using completely 
different tests for disease progress monitoring. 
According to de Carvalho et al., electromyography 
as well as nerve conduction and MUNE are used to 
monitor the disease progression [25]. Higashihara 
and Sonoo used the analysis of the resting record and 
MUP to diagnose and assess the course of ALS [26]. In 
our studies, we used the aforementioned electromy-
ography as well as clinical testing. Banach and Rako-
wicz used the same electromyography as the authors 
for preliminary diagnosis of ALS and MUNE, to assess 
the disease progression [11].
In our own studies, we showed the statistically 
significant prolonged duration of MUP of the muscles 
subjected to testing in the course of the half-year ob-
servation. The analysis of the results is consistent with 
the remarks of de Carvalho et al., who deemed that 
the duration of MUP is the best reinnervation indi-
cator at the early stage of the disease and most often 
shows variability in the disease course from among 
all the MUP parameters [27]. Jacobsen et al. consider 
the MUNE methods as more sensitive than the assess-
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ment of MUP duration to diagnose and monitor nerve 
and muscle disorders in ALS patients [28]. 
The assessment of denervation potentials showed 
no significant differences within the period of 6 months 
in our studies. 
de Carvalho et al. found that in the case of some 
patients with serious atrophy of first dorsal interos-
seous muscles, the incidence rate of fasciculation was 
increasing as the disease progressed [29].
The analysis of test results showed significant 
intensification in abnormal gait in the course of the 
half-year observation, which is reflected in the results 
of the 6-metre walk test and the 10-minute walk test.
The results of the electrophysiology studies ob-
tained in the course of A, B, and C measurements, 
especially the gradually prolonging duration of MUP, 
were reflected in the abnormal gait of the patients.
Jawdat et al. showed in their paper that in the case 
of bulbar-onset ALS patients, the disease progresses 
much faster and is more visible [2]. We showed in our 
analyses a significant deterioration in the electromyo-
graphic parameters and clinical tests in the course of 
a  6-month observation in a  similar manner in both 
groups, namely patients with bulbar- and limb-onset 
ALS. These results do not confirm the earlier findings.
The authors wish to emphasise that the assess-
ment of MUP duration of particular muscles may be 
beneficial for monitoring the ALS progression.
Conclusions
The progressing loss of nerve and muscle function 
as a result of motor neuron loss is reflected in walking 
deterioration in ALS patients. The gradually increas-
ing MUP duration of particular muscles is concomi-
tant to the increasing abnormal gait. The assessment 
of the MUP duration of particular muscles may serve 
to monitor the ALS progression.
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